Oral Metformin for Treatment of ABCA4 Retinopathy | MicrobiomeTrials← Back to trialsNCT04545736
Oral Metformin for Treatment of ABCA4 Retinopathy
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2020-11-23Est. Completion: 2028-02-02
Enrollment target: 55 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- University of Michigan, Ann Arbor, Michigan, United States
Other microbiome trials you might be interested in
Retinal DegenerationABCA4-Related Retinopathies
Background:
\- The ABCA4 gene contains a blueprint for the ABCA4 protein. When this protein is absent or faulty (such a…
Bethesda, United States
Stargardt Disease
This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age,…
Phoenix, United StatesEst. completion Oct 2029